Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study by Rucker Wright et al. found that hair care practices, particularly traction on relaxed hair, are associated with an increased risk of traction alopecia in African American girls.

In this analysis, JAK inhibitors were found to provide clinically meaningful and durable hair regrowth in pediatric alopecia areata, outperforming traditional therapies with a manageable safety profile.

In this case study, a tick bite from the genus Ixodes in a 9-year-old girl was associated with the development of localized alopecia areata, resembling telogen effluvium, which resolved completely in less than three months.

This study reports two cases of hair loss outcomes in patients using dupilumab for atopic dermatitis, with one showing improvement in alopecia universalis and another experiencing worsening of alopecia totalis.

This paper discusses a consensus statement from European experts recommending systemic JAK inhibitors as first-line therapy for moderate to severe alopecia areata.

This study found that tofacitinib was a safe and effective treatment for patients with moderate-to-severe alopecia areata, with a significant percentage achieving notable reductions in their Severity of Alopecia Tool scores after 18 months.

This study reported that a novel ionic liquid delivery system combining ferulic acid and finasteride enhanced the solubility, skin permeation, and effectiveness in promoting hair regrowth in androgenetic alopecia mice, suggesting an improved topical treatment approach.

This study observed that infants exposed to diazoxide in utero exhibited abnormal hair growth and, in some cases, impaired glucose tolerance, particularly those born to diabetic mothers.

This source reports that recent research highlights the effectiveness and tolerability of oral JAK inhibitors for treating moderate to severe alopecia areata, although further placebo-controlled studies are needed to confirm their long-term safety and efficacy.

This article reviews IFAP syndrome, an X-linked genetic disorder characterized by ichthyosis follicularis, alopecia, and photophobia, and reports no new clinical findings.

Potassium iodide prevents hair loss and reduces toxicity from thallium acetate.

This review covers the current status of the interstitial pneumonia with autoimmune features (IPAF) category, pointing out the need for revision of its criteria to establish it as a standalone diagnostic term, but reports no new clinical findings.

This study highlights the use of dermatoscopy as a valuable tool for diagnosing and monitoring alopecia areata, noting that specific hair shaft alterations such as exclamation-mark hairs and black dots are indicators of active disease, while vellus hairs signal early regrowth.

This study found that dermatoscopic features can distinguish between tinea capitis and alopecia areata in children, with tinea capitis commonly showing comma hairs and alopecia areata showing exclamation mark hairs.

Access to JAK inhibitors for alopecia areata should be improved in the Military Healthcare System.

In this study, trichoscopy significantly improved diagnostic accuracy in non-cicatricial alopecia, identifying alopecia areata as the most common cause and effectively aiding diagnosis in 28.2% of ambiguous cases.

This study found that oral baricitinib was more effective than methotrexate in treating severe alopecia areata, with significant improvements in SALT scores over six months.

This case study reports that tofacitinib effectively treated alopecia areata in a patient with Crohn's disease and maintained her Crohn's disease management.

In this case report, researchers described a two-year-old girl with Vitamin D dependent rickets Type II, noting elevated 1,25-dihydroxyvitamin D3 and alopecia, and observed limited treatment response likely due to poor compliance.

This review examines the pathophysiological mechanisms and emerging targeted treatments for alopecia areata, particularly highlighting the efficacy of oral JAK inhibitors over other less effective alternatives.

This study found that patients with alopecia areata had significantly lower serum 25(OH)D levels, which may be associated with increased disease severity.

This study found that alopecia areata can occur due to local pressure from extraoral orthodontic appliances, with hair regrowth associated with relieving the pressure.

This study found that 90% of pediatric patients with alopecia areata had comorbidities, including allergic rhinitis and atopic dermatitis, with localized AA being associated with better treatment outcomes and fewer relapses compared to non-localized forms.

This study found that different stabilizing mutations in Aux/IAA proteins affect root hair development in Arabidopsis by disrupting the auxin response and suggest a model where the relative abundance of these proteins determines root hair initiation.

In this review, the authors highlight the FDA approval of Ritlecitinib, the first oral treatment specifically for moderate to severe alopecia areata in patients aged 12 and older, marking a significant advancement in managing this condition.

This study observed significant repigmentation in localized stable vitiligo lesions treated with oral baricitinib, with even more improvement when combined with topical tacrolimus, and reported no side effects.

The study initially suggested a genetic link between thyroid issues and hair loss.

This study in a real-world setting found that baricitinib was effectively reducing disease severity in severe alopecia areata patients over 52 weeks, with 37.20% of participants achieving significant improvement and 72.40% experiencing mild or no adverse events.

Alopecia areata is an autoimmune disorder causing hair loss, linked to specific hair follicle antigens and genetic factors.

This study found that patients with alopecia areata had significantly lower serum vitamin D levels compared to controls, but these levels did not impact disease severity or pattern.